Bristol-Myers Faces More Scrutiny

Bristol-Myers Squibb Co.'s third-quarter earnings were battered by generic competition to its bestselling drug, the blood thinner Plavix, and it disclosed that a federal monitor's investigation into its handling of a dispute over Plavix's patent has broadened to include possible securities violations.

It was unclear whether the widening scope of the probe being conducted by former federal judge Frederick B. Lacey means he has uncovered new wrongdoing in the three-month-old Plavix saga. Bristol-Myers said the development...